Biogen Inc.: FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly

Related Keywords

Puerto Rico ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Timothym Miller ,Jean Swidler ,Tudur Smith ,Oligonucleotide Tofersen ,Chuck Triano ,Christophera Viehbacher ,Jack Cox ,Exchange Commission ,National Institute Of Neurological Disorders ,Neurofilament Proteins In Health ,Linkedin ,Facebook ,Drug Administration ,Center At Washington University School Of Medicine ,Twitter ,Ionis Pharmaceuticals Inc ,Youtube ,Nasdaq ,Copay Program ,Ionis Pharmaceuticals ,Chief Executive Officer ,New England Journal ,Washington University School ,Assistance Programs ,Amyotrophic Lateral Sclerosis ,Continuous Commitment ,Neurological Disorders ,Neurofilament Proteins ,Cold Spring Harb Perspect ,Antisense Oligonucleotide Tofersen ,Biogen ,Migrants ,Ccelerated ,Approval ,Qalsody ,Ofersen ,Sod1 ,Major ,Cientific ,Advancement ,First ,Treatment ,Target ,Enetic ,Cause ,